Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The J591 minibody is an engineered antibody fragment designed to target the extracellular domain of Prostate Specific Membrane Antigen (PSMA). It is a homodimer consisting of two single-chain variable fragments (scFv) derived from the deimmunized huJ591 monoclonal antibody, each linked to a human IgG1 CH3 domain via an artificial hinge sequence. This format is optimized for pharmacokinetics, providing rapid tumor localization and faster blood clearance compared to full-length antibodies, which enhances its utility as an imaging agent for positron emission tomography (PET) and single-photon emission computed tomography (SPECT). When conjugated with chelators like DOTA and labeled with radionuclides such as Copper-64, Iodine-124, or Indium-111, it serves as a high-contrast diagnostic tool for staging and monitoring prostate cancer and other solid tumors characterized by PSMA-expressing neovasculature. It also holds potential for radioimmunotherapy when labeled with beta-emitting isotopes like Yttrium-90.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on J591 minibody.